> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Rivoceranib Gets Orphan Status for Liver Cancer
- URL: https://www.fdaweb.com/rivoceranib-gets-orphan-status-for-liver-cancer/
- Published: 2021-11-11T12:00:00.000Z
- Updated: 2026-09-14T17:22:06.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5150562

FDA has granted Elevar Therapeutics an orphan drug designation for rivoceranib and its use for treating hepatocellular carcinoma (HCC). The company says a Phase 3 trial is being conducted in collaboration with Jiangsu Hengrui Medicine Co. in patients with advanced HCC who have not received prior systemic therapy. Rivoceranib is described by Elevar as a highly potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), a primary pathway for tumor angiogenesis. Rivoceranib, under the name apatinib, was approved in China in 2014 as a single agent for treating gastric cancer and second-line advanced HCC in 2020.